Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II multi-center exploratory study to identify biomarkers predictive of
clinical response to aflibercept in patients with metastatic colorectal cancer who have
failed first-line therapy, consisting of an oxaliplatin-containing regimen in combination
with bevacizumab. Patients will consent to a needle core biopsy of a liver metastatic lesion
prior to starting treatment and blood samples will be collected from study patients during
treatment.
An exploratory pharmacoeconomic analysis will be performed to evaluate productivity loss,
quality of life and resource utilization while on treatment with aflibercept.
Phase:
Phase 2
Details
Lead Sponsor:
CR-CSSS Champlain-Charles-Le Moyne
Collaborators:
Quebec Clinical Research Organization in Cancer Regeneron Pharmaceuticals Sanofi